Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD : A Simulation Study From DA VINCI. / Vallejo-Vaz, Antonio J; Bray, Sarah; Villa, Guillermo; Brandts, Julia; Kiru, Gaia; Murphy, Jennifer; Banach, Maciej; De Servi, Stefano; Gaita, Dan; Gouni-Berthold, Ioanna; Kees Hovingh, G.; Jozwiak, Jacek J.; Jukema, J. Wouter; Gabor Kiss, Robert; Kownator, Serge; Iversen, Helle K.; Maher, Vincent; Masana, Luis; Parkhomenko, Alexander; Peeters, André; Clifford, Piers; Raslova, Katarina; Siostrzonek, Peter; Romeo, Stefano; Tousoulis, Dimitrios; Vlachopoulos, Charalambos; Vrablik, Michal; Catapano, Alberico L.; Poulter, Neil R.; Ray, Kausik K.; On behalf of the DA VINCI Study Investigators.
In: Cardiovascular Drugs and Therapy, Vol. 37, No. 5, 2023, p. 941-953.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD
T2 - A Simulation Study From DA VINCI
AU - Vallejo-Vaz, Antonio J
AU - Bray, Sarah
AU - Villa, Guillermo
AU - Brandts, Julia
AU - Kiru, Gaia
AU - Murphy, Jennifer
AU - Banach, Maciej
AU - De Servi, Stefano
AU - Gaita, Dan
AU - Gouni-Berthold, Ioanna
AU - Kees Hovingh, G.
AU - Jozwiak, Jacek J.
AU - Jukema, J. Wouter
AU - Gabor Kiss, Robert
AU - Kownator, Serge
AU - Iversen, Helle K.
AU - Maher, Vincent
AU - Masana, Luis
AU - Parkhomenko, Alexander
AU - Peeters, André
AU - Clifford, Piers
AU - Raslova, Katarina
AU - Siostrzonek, Peter
AU - Romeo, Stefano
AU - Tousoulis, Dimitrios
AU - Vlachopoulos, Charalambos
AU - Vrablik, Michal
AU - Catapano, Alberico L.
AU - Poulter, Neil R.
AU - Ray, Kausik K.
AU - On behalf of the DA VINCI Study Investigators
N1 - Publisher Copyright: © 2022, The Author(s).
PY - 2023
Y1 - 2023
N2 - Purpose: Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (< 70 vs. < 55 mg/dl, respectively). In the DA VINCI study, residual cardiovascular risk was predicted in ASCVD patients. The extent to which relative and absolute risk might be lowered by achieving ACC/AHA versus ESC/EAS LDL-C recommended approaches was simulated. Methods: DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of < 70 or < 55 mg/dl (LDL-C of 69 or 54 mg/dl, respectively) was calculated. Relative and absolute risk reductions (RRRs and ARRs) were simulated. Results: Of the 2039 patients, 61% did not achieve LDL-C < 70 mg/dl. For patients with LDL-C ≥ 70 mg/dl, median (interquartile range) baseline LDL-C and 10-year CVR were 93 (81–115) mg/dl and 32% (25–43%), respectively. Median LDL-C reductions of 24 (12–46) and 39 (27–91) mg/dl were needed to achieve an LDL-C of 69 and 54 mg/dl, respectively. Attaining ACC/AHA or ESC/EAS goals resulted in simulated RRRs of 14% (7–25%) and 22% (15–32%), respectively, and ARRs of 4% (2–7%) and 6% (4–9%), respectively. Conclusion: In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach. Graphical abstract: [Figure not available: see fulltext.]
AB - Purpose: Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (< 70 vs. < 55 mg/dl, respectively). In the DA VINCI study, residual cardiovascular risk was predicted in ASCVD patients. The extent to which relative and absolute risk might be lowered by achieving ACC/AHA versus ESC/EAS LDL-C recommended approaches was simulated. Methods: DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of < 70 or < 55 mg/dl (LDL-C of 69 or 54 mg/dl, respectively) was calculated. Relative and absolute risk reductions (RRRs and ARRs) were simulated. Results: Of the 2039 patients, 61% did not achieve LDL-C < 70 mg/dl. For patients with LDL-C ≥ 70 mg/dl, median (interquartile range) baseline LDL-C and 10-year CVR were 93 (81–115) mg/dl and 32% (25–43%), respectively. Median LDL-C reductions of 24 (12–46) and 39 (27–91) mg/dl were needed to achieve an LDL-C of 69 and 54 mg/dl, respectively. Attaining ACC/AHA or ESC/EAS goals resulted in simulated RRRs of 14% (7–25%) and 22% (15–32%), respectively, and ARRs of 4% (2–7%) and 6% (4–9%), respectively. Conclusion: In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach. Graphical abstract: [Figure not available: see fulltext.]
KW - Atherosclerotic cardiovascular disease
KW - Cardiovascular disease prevention
KW - Cardiovascular risk
KW - LDL-C
KW - Lipid-lowering
KW - Statins
U2 - 10.1007/s10557-022-07343-x
DO - 10.1007/s10557-022-07343-x
M3 - Journal article
C2 - 35567726
AN - SCOPUS:85130226697
VL - 37
SP - 941
EP - 953
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 5
ER -
ID: 314280240